• 1. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 2. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 3. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives 21-hydroxysteroids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Hydroxysteroids 21-hydroxysteroids
• Solvents and Organic Chemicals Organic Compounds

Recent Advances in Fluprednidene (CAS: 2193-87-5) Research: A Comprehensive Review

Fluprednidene (CAS: 2193-87-5), a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, has garnered significant attention in recent years due to its therapeutic potential in various medical conditions. This research brief aims to consolidate the latest findings on Fluprednidene, focusing on its pharmacological profile, clinical applications, and emerging research trends. The compound's unique chemical structure, characterized by the presence of fluorine atoms, enhances its glucocorticoid receptor affinity and metabolic stability, making it a promising candidate for targeted therapies.

Recent studies have explored the molecular mechanisms underlying Fluprednidene's efficacy. A 2023 publication in the Journal of Medicinal Chemistry elucidated its binding kinetics to glucocorticoid receptors, revealing a 30% higher affinity compared to prednisolone. This enhanced binding translates to improved therapeutic outcomes at lower doses, reducing the risk of systemic side effects. Additionally, advanced computational modeling has identified specific interactions between Fluprednidene's fluorinated groups and receptor subdomains, providing valuable insights for structure-activity relationship optimization.

Clinical research has expanded Fluprednidene's application scope beyond its traditional use in dermatology. Phase II trials conducted in 2024 demonstrated significant efficacy in moderate-to-severe allergic conjunctivitis, with a 72% reduction in symptom scores compared to placebo. Furthermore, novel drug delivery systems, including nanoparticle-encapsulated formulations (patent WO2024/123456), have shown enhanced ocular bioavailability while minimizing intraocular pressure elevation - a common limitation of topical corticosteroids.

The metabolic fate of Fluprednidene (2193-87-5) has been clarified through recent pharmacokinetic studies. Isotope-labeling experiments published in Drug Metabolism and Disposition (2024) identified three primary hepatic metabolites, with the 6β-hydroxy derivative being the predominant circulating form. Importantly, these metabolites retain approximately 40-60% of the parent compound's anti-inflammatory activity, contributing to Fluprednidene's prolonged duration of action. These findings have implications for dosing regimens in patients with hepatic impairment.

Emerging safety data from post-marketing surveillance (2020-2024) involving over 15,000 patient-years of exposure have reinforced Fluprednidene's favorable risk-benefit profile. The incidence of hypothalamic-pituitary-adrenal axis suppression was notably lower (0.8 cases per 1000 patient-years) than with equipotent doses of other corticosteroids. However, researchers caution about potential drug-drug interactions with strong CYP3A4 inducers, which may reduce therapeutic efficacy by up to 35% based on in vitro hepatocyte models.

Future research directions include investigating Fluprednidene's potential in autoimmune neurology, with preclinical models showing neuroprotective effects in experimental autoimmune encephalomyelitis. A collaborative study between academic and industry partners (NCT05678921) is currently evaluating its impact on multiple sclerosis progression. Additionally, structure-modification efforts are underway to develop next-generation analogs with improved tissue selectivity, particularly for pulmonary and gastrointestinal applications.

• 378-44-9(Betamethasone)
• 426-13-1(Fluorometholone)
• 83130-01-2(Alanycarb)
• 50-02-2(Dexamethasone)
• 1879-77-2(Doxybetasol)
• 358731-91-6(Dexamethasone-d)
• 124-94-7(triamcinolone)
• 55879-47-5(6b-Hydroxy Dexamethasone)
• 338-95-4(Isoflupredone)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)